| Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, ... Cancer 128 (6), 1194-1205, 2022 | 36 | 2022 |
| Age‐related deep white matter changes in myelin and water content: A T2 relaxometry study E Papadaki, E Kavroulakis, G Kalaitzakis, D Karageorgou, D Makrakis, ... Journal of Magnetic Resonance Imaging 50 (5), 1393-1404, 2019 | 33 | 2019 |
| Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective … K Rounis, D Makrakis, AP Tsigkas, A Georgiou, N Galanakis, C Papadaki, ... Translational Lung Cancer Research 10 (8), 3538, 2021 | 28 | 2021 |
| Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective … K Rounis, D Makrakis, C Papadaki, A Monastirioti, L Vamvakas, ... PloS one 16 (6), e0252537, 2021 | 23 | 2021 |
| Circulating MicroRNAs regulating DNA damage response and responsiveness to cisplatin in the prognosis of patients with non-small cell lung cancer treated with first-line … C Papadaki, A Monastirioti, K Rounis, D Makrakis, K Kalbakis, C Nikolaou, ... Cancers 12 (5), 1282, 2020 | 18 | 2020 |
| Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a ‘real-life’setting M Skribek, K Rounis, D Makrakis, S Agelaki, D Mavroudis, L De Petris, ... Cancers 12 (12), 3707, 2020 | 16 | 2020 |
| Cerebral perfusion disturbances in chronic mild traumatic brain injury correlate with psychoemotional outcomes E Papadaki, E Kavroulakis, K Manolitsi, D Makrakis, E Papastefanakis, ... Brain imaging and behavior 15, 1438-1449, 2021 | 12 | 2021 |
| Correlation of clinical parameters with intracranial outcome in non-small cell lung cancer patients with brain metastases treated with Pd-1/Pd-L1 inhibitors as monotherapy K Rounis, M Skribek, D Makrakis, L De Petris, S Agelaki, S Ekman, ... Cancers 13 (7), 1562, 2021 | 12 | 2021 |
| Association between sites of metastasis and outcomes with immune checkpoint inhibitors in advanced urothelial carcinoma D Makrakis, R Talukder, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, ... Clinical genitourinary cancer 20 (5), e440-e452, 2022 | 11 | 2022 |
| Multinodular and vacuolating neuronal tumor incidentally discovered in a young man: conventional and advanced MRI features D Makrakis, S Veneris, E Papadaki Radiology Case Reports 13 (5), 960-964, 2018 | 11 | 2018 |
| Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma D Makrakis, DR Bakaloudi, R Talukder, GI Lin, LN Diamantopoulos, ... Clinical genitourinary cancer 21 (2), 286-294, 2023 | 10 | 2023 |
| Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint … K Rounis, C Papadaki, D Makrakis, A Monastirioti, L Vamvakas, ... Annals of Oncology 30, ii61, 2019 | 9 | 2019 |
| Intravesical BCG and incidence of Alzheimer disease in patients with bladder cancer: Results from an administrative dataset D Makrakis, SK Holt, C Bernick, P Grivas, JL Gore, JL Wright Alzheimer Disease & Associated Disorders 36 (4), 307-311, 2022 | 8 | 2022 |
| Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances KS Rallis, D Makrakis, IA Ziogas, G Tsoulfas World Journal of Clinical Oncology 13 (6), 448, 2022 | 8 | 2022 |
| Association of the time to immune checkpoint inhibitor (ICI) initiation and outcomes with second line ICI in patients with advanced urothelial carcinoma R Talukder, D Makrakis, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, ... Clinical genitourinary cancer 20 (6), 558-567, 2022 | 6 | 2022 |
| Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune … S Agelaki, K Rounis, C Papadaki, AA Monastirioti, L Vamvakas, ... Journal of Clinical Oncology 37 (15_suppl), 9099-9099, 2019 | 6 | 2019 |
| Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC):“Real world” experience DR Bakaloudi, R Talukder, GI Lin, D Makrakis, LN Diamantopoulos, ... Clinical genitourinary cancer 21 (5), 584-593, 2023 | 5 | 2023 |
| Brain SPECT and perfusion MRI: do they provide complementary information about the tumour lesion and its grading? M Daboudi, E Papadaki, A Vakis, G Chlouverakis, D Makrakis, ... Clinical Radiology 74 (8), 652. e1-652. e9, 2019 | 5 | 2019 |
| Response and outcomes to immune checkpoint inhibitors in advanced urothelial cancer based on prior intravesical bacillus calmette-guerin R Talukder, D Makrakis, LN Diamantopoulos, L Carril-Ajuria, ... Clinical genitourinary cancer 20 (2), 165-175, 2022 | 4 | 2022 |
| Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study. VS Koshkin, Y Sun, D Freeman, CK Osterman, C Su, D Natesan, ... Journal of clinical oncology 39 (6_suppl), 443-443, 2021 | 4 | 2021 |
Kostas RounisVerified email at rounis.gr
